Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
2024年7月16日 - 9:00PM
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a
clinical-stage biotechnology company developing a new generation of
targeted antitumor virotherapies, today announced the appointment
of Mark Gilbert, MD, scientist emeritus at the National Institutes
of Health (NIH), to its Medical Advisory Board. This addition
increases the board’s membership to eight.
Dr. Gilbert most recently served as the Chief of
the Neuro-Oncology Branch at NIH from 2014 to 2024. Under
Dr. Gilbert’s leadership, his team of laboratory and clinical
investigators conducted groundbreaking research that advanced
science in the brain tumor field. He developed robust clinical
trials based on strong preclinical findings, improving patient
outcomes through innovative combination treatments and precision
medicine approaches.
“We are honored that Dr. Gilbert has recognized the
revolutionary science at Calidi Biotherapeutics in both tumoral and
glioblastoma cancer treatment. He joins other luminaries on our
Medical Advisory Board who also believe in our stem-cell based
therapy’s potential to offer hope and better results for those with
cancer,” said Allan Camaisa, CEO of Calidi.
“What intrigued me about Calidi’s SNV1 and NNV1 is its
versatility and ability to potentially address rare cancer
diseases affecting about 25% of cancer patients,” stated Dr
Gilbert.
Before joining NIH, Dr. Gilbert practiced under another Medical
Advisory Board member, world-renowned oncologist Dr. Alfred Yung,
at MD Anderson in Houston from 1990 to 2014. Prior to that, Dr.
Gilbert worked at UPMC in Pittsburgh, Emory University in Atlanta,
and Johns Hopkins in Baltimore. Dr. Gilbert received his Doctor of
Medicine degree from Johns Hopkins University in 1982 (Alpha Omega
Alpha) and completed residencies in internal medicine and
neurology, as well as a neuro-oncology fellowship at Johns
Hopkins.
“I am deeply honored to join such a dynamic team of scientists
and business leaders at Calidi. They have scientifically proven a
game-changing therapy that I am happy to support, as many of my
colleagues on the Medical Advisory Board have done,” said Dr.
Gilbert.
Other members of the Calidi Biotherapeutics Medical Advisory
Board include W.K. Alfred Yung, MD (MD Anderson); Karen Aboody, MD
(City of Hope), Santosh Kesari, MD/PhD (Saint John’s Cancer
Institute); Matt Lesniak, MD (Northwestern University); Ewa
Carrier, MD (FibroGen); Dmitriy Zamarin, MD/PhD (Mount Sinai);
Ashok Srivastava MD/PhD (CliniFomatrix).
Mr. Camaisa added, “Dr Gilbert’s expertise and experience will
aid in guiding us on developing innovative, multi-institutional
studies, partnering with national centers of excellence and key
components of the NCI and NIH through Cooperative Research
Development Agreements (CRADAs) and other submissions. This will
enable us to do some groundbreaking research to help people.”
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer. Calidi’s novel stem cell-based
platforms are utilizing potent allogeneic stem cells capable of
carrying payloads of oncolytic viruses for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s clinical stage off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses leading to enhanced efficacy and improved patient
safety. Calidi’s preclinical off-the-shelf enveloped virotherapies
are designed to target disseminated solid tumors. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please
visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for
purposes of the “safe harbor” provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as
“anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predicts,” “project,” “should,” “towards,” “would” as
well as similar terms, are forward-looking in nature, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements concerning upcoming key milestones
(including the reporting of interim clinical results and the dosing
of patients), planned clinical trials, and statements relating to
the safety and efficacy of Calidi’s therapeutic candidates in
development. Any forward-looking statements contained in this
discussion are based on Calidi’s current expectations and beliefs
concerning future developments and their potential effects and are
subject to multiple risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth or
implied in such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that Calidi
is not able to raise sufficient capital to support its current and
anticipated clinical trials, the risk that early results of
clinical trials do not necessarily predict final results and that
one or more of the clinical outcomes may materially change
following more comprehensive review of the data, and as more
patient data becomes available, the risk that Calidi may not
receive FDA approval for some or all of its therapeutic candidates.
Other risks and uncertainties are set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward-Looking
Statements” in the Company’s Registration Statements filed with the
SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on
October 6, 2023, on Form S-1 filed on January 29, 2024, as amended
on February 7, 2024, on Form 10-K filed on March 15, 2024, and
Final Prospectus filed on April 17, 2024.
For Investors and Media:
Stephen Thesing
IR@Calidibio.com